Halozyme Therapeutics Inc. (NASDAQ:HALO) raised its 2026 and multi-year financial guidance, citing accelerating royalty revenue, expanding partnerships, and recent acquisitions that management says strengthen the company’s long-term growth profile.
The company released preliminary fiscal 2025 sales of $1.385 billion-$1.4 billion, up 36% to 38% year over year, with royalty revenues of $865 million-$870 million.
Looking ahead, Halozyme expects 2026 total revenue to grow between 23% and 30% year over year, driven primarily by royalties and API product sales.
Halozyme Therapeutics raises fiscal 2026 revenue guidance from the prior range of $1.43 billion-$1.53 billion to $1.71 billion-$1.81 billion.
Royalty revenue alone is projected at $1.13 billion to $1.17 billion, representing 30% to 35% growth and reaching the $1 billion mark a year earlier than previously anticipated.
“In the near-term, our strong 2026 total revenue expectations of 23% to 30% year‑over‑year growth underscore the strength of our royalty revenue, which is projected to exceed $1 billion in 2026, growing at 30% to 35% versus prior year. This is one year earlier than previously projected,” said Helen Torley, President and CEO.
“By the end of 2026, we project we will have 15 partner programs in development and have signed three or more new drug delivery licensing agreements, expanding the reach and growing our opportunity through our diversified drug delivery portfolio. Taken together, these drivers reinforce our confidence in delivering durable revenue growth well into the 2040s and support our conviction in Halozyme’s long‑term growth profile, which will deliver sustained value for shareholders,” Torley added.
The company also forecast adjusted EBITDA of $1.125 billion to $1.205 billion in 2026, including approximately $60 million in new investments tied to Hypercon and Surf Bio.
Non-GAAP diluted earnings per share are expected to range from $7.75 to $8.25, from previous guidance of $6.50-$7.00, excluding any impact from potential share repurchases.
Halozyme said it acquired Surf Bio for $300 million upfront, with up to $100 million in additional milestone payments.
HALO Price Action: Halozyme Therapeutics shares were up 2.95% at $72.29 at the time of publication on Wednesday, according to Benzinga Pro data.
Photo by Aria Armoko via Shutterstock
Recent Comments